Traws Pharma, Inc. (TRAW)
| Market Cap | 8.74M -34.6% |
| Revenue (ttm) | n/a +1,134.5% |
| Net Income | -16.44M |
| EPS | -1.47 |
| Shares Out | 15.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,461 |
| Open | 0.5600 |
| Previous Close | 0.5453 |
| Day's Range | 0.5501 - 0.5700 |
| 52-Week Range | 0.4301 - 3.2650 |
| Beta | 1.61 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About TRAW
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhib... [Read more]
Financial Performance
Financial StatementsNews
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to t...
Traws Pharma Quarterly report: Q2 2026
Traws Pharma has published its Q2 2026 quarterly earnings report on August 14, 2026.
Traws Pharma Earnings release: Q2 2026
Traws Pharma released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Traws Pharma Transcript: AGM 2026
The meeting established a quorum and approved all five proposals, including director elections, incentive plan amendments, auditor ratification, and share issuance upon warrant exercise. No shareholder questions were received during the session.
Traws Pharma files $139.19M mixed securities shelf
16:03 EDT Traws Pharma (TRAW) files $139.19M mixed securities shelf
Traws Pharma Registration statement: Registration filing
Traws Pharma filed a registration statement on July 1, 2026, providing details about a securities offering with the SEC.
Traws Pharma provides update on tivoxavir marboxil program
Traws Pharma (TRAW) announced that an updated toxicology data package is in the process of being developed in response to information requirements from the United Kingdom’s Medicines and Healthcare Pr...
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to e...
Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes downgraded Traws Pharma (TRAW) to Neutral from Buy with a price target of $1, down from $8, after the company said its planned test of…
Traws Pharma downgraded to Neutral from Buy at Ladenburg
Ladenburg analyst Kevin DeGeeter downgraded Traws Pharma (TRAW) to Neutral from Buy without a price target citing the company’s setback in flu and its balance sheet “overhang.” Published first on…
Traws Pharma influenza challenge study deferred following MHRA review
Traws Pharma (TRAW) announced that the planned test of tivoxavir marboxil in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program…
Traws Pharma Provides Regulatory Update on Influenza Program
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats,...
Traws Pharma Proxy statement: Proxy filing
Traws Pharma filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Traws Pharma Proxy statement: Proxy filing
Traws Pharma filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Traws Pharma announces antiviral program targeting Hantavirus, Ebola
Traws Pharma (TRAW) announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio. The investigational combination utilizes a unique “dual-strike” mecha...
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low ...
Traws Pharma Proxy statement: Proxy filing
Traws Pharma filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
Traws Pharma Quarterly report: Q1 2026
Traws Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
Traws Pharma Earnings release: Q1 2026
Traws Pharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Traws Pharma files to sell 35.9M shares of common stock for holders
17:05 EDT Traws Pharma (TRAW) files to sell 35.9M shares of common stock for holders
There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.
It's been a struggle to secure funding for hantavirus research because these viruses haven't been a priority.
Traws Pharma Registration statement: Registration filing
Traws Pharma filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ta...
Traws Pharma Earnings Call Transcript: Q4 2025
Significant progress was made advancing a next-gen influenza antiviral, supported by $60M in new financing. Net income turned positive in 2025, and key clinical studies are planned in the UK, while US trials face an FDA clinical hold pending toxicology data resolution.